Quick Answer
BIOMARIN PHARMACEUTICAL INC reported R&D Expense of $921.93 million for fiscal year 2025.
BIOMARIN PHARMACEUTICAL INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $921.93M | +23.4% |
| 2024 | $747.18M | +0.1% |
| 2023 | $746.77M | +15.0% |
| 2022 | $649.61M | +3.3% |
| 2021 | $628.79M | +0.1% |
| 2020 | $628.12M | -12.2% |
| 2019 | $715.01M | +2.7% |
| 2018 | $696.33M | +14.0% |
| 2017 | $610.75M | -7.7% |
| 2016 | $661.90M | +4.3% |
| 2015 | $634.81M | +37.5% |
| 2014 | $461.54M | +30.1% |
| 2013 | $354.78M | +17.4% |
| 2012 | $302.22M | +41.0% |
| 2011 | $214.37M | +45.5% |
| 2010 | $147.31M | +28.0% |
| 2009 | $115.12M | +23.4% |
| 2008 | $93.29M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $409.48M | +121.5% | +153.8% |
| June 30, 2025 | $161.31M | -12.2% | +1.6% |
| March 31, 2025 | $158.73M | -22.6% | -14.2% |
| September 30, 2024 | $184.90M | -3.4% | +0.6% |
| June 30, 2024 | $183.79M | +3.6% | -10.3% |
| March 31, 2024 | $204.99M | +19.3% | +7.1% |
| September 30, 2023 | $191.31M | +21.2% | +7.9% |
| June 30, 2023 | $177.36M | +12.1% | +3.2% |
- BIOMARIN PHARMACEUTICAL INC showed an increase of +23.4% in R&D Expense compared to the prior fiscal year.
- Over the 2008–2025 period, BIOMARIN PHARMACEUTICAL INC’s r&d expense has grown by 888.2% (from $93.29 million to $921.93 million).
- The most recent figure is from BIOMARIN PHARMACEUTICAL INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: